^
Association details:
Biomarker:MET amplification
Cancer:Glioblastoma
Drug:Recentin (cediranib) (VEGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

Excerpt:
Her tumor was found to have MET gene amplification by a dual-color FISH assay...After five postradiation cycles of temozolomide and cediranib, she developed headaches, fatigue, disorientation, and short-term memory loss…. A cranial MRI examination demonstrated increased size of the contrast-enhancing lesion and significantly increased surrounding T2/FLAIR hyperintensity consistent with progressive disease.
DOI:
10.1200/JCO.2011.38.4586